FDA panel supports broadening access to peptides popular on the gray market

An FDA advisory panel voted to recommend reclassifying six peptide therapies for compounding pharmacy production, overriding the agency's scientific objections and enabling legal domestic access to compounds currently sold only on unregulated markets. The move reflects political pressure from Health Secretary Kennedy and conflicts of interest on the newly stacked panel.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.